{"filings":[{"id":96685,"accession_number":"0001193125-26-215674","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Lexeo Therapeutics Q1 net loss $20.2M; cash $227.6M; LX2006 pivotal trial protocol submitted to FDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $20.2M ($0.25/share) vs $32.7M ($0.99) in Q1 2025; R&D $15.7M, G&A $6.6M.","Cash, equivalents & investments $227.6M at March 31, 2026; expected runway into 2028.","LX2006 SUNRISE-FA2 pivotal protocol and SAP submitted to FDA; initiation expected Q2 2026.","Appointed Laura Sepp-Lorenzino, Ph.D., former CSO of Intellia, to Board of Directors.","ASGCT presentations: LX2006 shows significant mFARS improvement vs natural history (p=0.003); LX2022 preclinical data."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96684,"accession_number":"0001193125-26-193927","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lexeo appoints Dr. Laura Sepp-Lorenzino to board and Science & Technology Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Sepp-Lorenzino appointed April 28, 2026; term expires at 2028 annual meeting.","She joins Science & Technology Committee; prior CSO of Intellia Therapeutics (2019-2025).","Compensation: $40k annual cash, initial option for 50,000 shares; first annual grant in 2027.","Previously held leadership roles at Vertex, Alnylam, and Merck in RNA therapeutics/oncology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110800,"accession_number":"0001193125-26-131792","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Lexeo reports FY2025 net loss $100M; cash $246.6M, runway into 2028; LX2006 pivotal trial on track for 1H2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss FY2025 $100.0M ($1.86/share) vs $98.3M ($3.09/share) in FY2024; Q4 loss $20.9M ($0.27).","R&D expenses FY2025 $63.8M vs $74.1M in FY2024; G&A $45.5M vs $31.7M.","Cash $246.6M as of Dec 31, 2025, expected to fund operations into 2028.","LX2006 for FA: FDA feedback on SUNRISE-FA 2 pivotal protocol expected Q2 2026; trial start 1H 2026.","Collaboration with Johnson & Johnson for targeted cardiac AAV delivery; new CMO Dr. Narinder Bhalla appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110799,"accession_number":"0001193125-26-039425","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"LXEO Head of Research Dr. Adler departs; transition agreement through July 31, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Adler stepped down as Head of Research effective February 1, 2026; will provide advisory services through July 31, 2026 or earlier termination.","Under transition agreement, Dr. Adler will receive up to $62,500 in monthly installments; service-vesting equity continues to vest during transition period.","Option exercise period extended to six months after transition end; additional $1,000 lump sum possible upon execution of supplemental release.","Transition agreement includes customary release of claims, non-disparagement, and cooperation provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110798,"accession_number":"0001193125-26-023339","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lexeo appoints COO and CMO; Eric Adler leaves to lead spin-off Myoventive","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jose Manuel Otero, former CTO, becomes COO effective Jan 2, 2026; base salary set at $510,000.","Narinder P. Bhalla appointed Chief Medical Officer effective Jan 20, 2026, succeeding Eric Adler.","Eric Adler steps down as executive officer to become CEO of Myoventive, co-founded by Lexeo, Perceptive Xontogeny, and venBio Partners.","Adler remains senior clinical and scientific advisor to Lexeo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110797,"accession_number":"0001193125-26-010091","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lexeo Therapeutics reports positive interim Phase 1/2 clinical data for LX2020 in PKP2-ACM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LX2020 generally well tolerated in 10 participants; no clinically significant complement activation observed","Mean PKP2 protein expression increased 93% in low-dose (n=2) and 162% in high-dose cohorts (n=5) by western blot","Non-sustained ventricular tachycardia reduced 22% (mean) in high-dose cohort (n=5); PVCs improved 14%","4 of 5 high-dose participants reported improvement on the PGIC patient-reported outcome scale","HEROIC-PKP2 enrollment completed Q4 2025; 12-month data for all high-dose participants expected Q4 2026"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127431,"accession_number":"0001193125-25-265755","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lexeo reports Q3 2025 net loss $20.3M; FDA open to accelerated BLA for LX2006; raised $154M equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA agreed to consider pooling ongoing Phase I/II LX2006 data with pivotal trial data for BLA; co-primary endpoint earlier than 12 months okayed.","FDA approved comparability between HEK293 and Sf9 manufacturing processes for LX2006; Sf9 process endorsed for pivotal study.","LX2006 interim data: 18-23% mean LVMI improvement at 6-12 months in abnormal-baseline patients; 2.0-point mean mFARS improvement (n=16).","Enrollment complete for LX2020 HEROIC-PKP2 Phase I/II (10 dosed); substantive data update expected January 2026.","Cash, equivalents, investments $122.8M at Sep 30, 2025; plus $153.8M net from October equity offering funds operations into 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127430,"accession_number":"0001193125-25-242652","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["1.01","2.02","3.02","8.01","9.01"],"status":"ready","headline":"Lexeo prices $135M offering; FDA open to faster LX2006 approval path","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced public offering of 15.625M shares at $8.00 and $10M private placement (pre-funded warrants) to Balyasny; gross proceeds ~$135M.","Preliminary cash, cash equivalents and investments of $122.8M as of Sept 30, 2025.","FDA indicated openness to accelerated BLA for LX2006 using pooled Phase I/II and pivotal study data; enhanced manufacturing comparability required.","LX2006 interim data: sustained or deepening improvements in LVMI and frataxin in majority of 16 participants at >=6 months follow-up.","LX2020: 9 participants dosed; one Grade 3 SVT resolved; low-dose cohort shows stable cardiac parameters; more data expected Jan 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127429,"accession_number":"0001193125-25-232514","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lexeo gets FDA feedback for LX2006 accelerated approval; interim data show LVMI reduction, mFARS improvement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA open to pooling ongoing Phase 1/2 data with pivotal study to support BLA for accelerated approval.","Abnormal-LVMI patients (n=6): 18% mean reduction at 6 months, 23% at 12 months, exceeding 10% FDA threshold.","All participants (n=16) >6-mo follow-up: 2.0-point mean mFARS improvement; 11 of 16 improved or stabilized.","LX2006 generally well tolerated; no Grade 3+ SAEs; no discontinuations; one Grade 2 asymptomatic myocarditis.","Lexeo plans to initiate LX2006 pivotal study as soon as possible in first half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144211,"accession_number":"0000950170-25-108426","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Lexeo reports Q2 net loss $26.1M, advances LX2006 with Breakthrough Therapy, appoints new CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $26.1M ($0.60/sh) vs $21.2M ($0.64/sh) in Q2 2024; cash $152.5M expected to fund operations into 2028.","LX2006 granted FDA Breakthrough Therapy designation based on interim data; registrational study expected early 2026.","Eight participants dosed in Phase I/II HEROIC-PKP2 trial of LX2020; interim data update expected H2 2025.","Closed $80M equity financing in May 2025; strategic partnership for non-viral RNA cardiac therapies.","Louis Tamayo appointed CFO effective Aug 15, 2025, succeeding Kyle Rasbach."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162557,"accession_number":"0000950170-25-091671","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lexeo stockholders elect two Class II directors, ratify KPMG as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Steven Altschuler, M.D. elected with 19,800,126 votes for and 2,775,771 withheld (5,374,056 broker non-votes).","Reinaldo Diaz elected with 19,986,796 votes for and 2,589,101 withheld (5,374,056 broker non-votes).","Ratification of KPMG LLP as independent auditor for FY2025: 27,929,327 for, 18,858 against, 1,768 abstain.","All proposals passed; no other matters were submitted to a vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162556,"accession_number":"0000950170-25-077377","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Lexeo raises $80M in private placement; cash runway into 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$80M from sale of 20.79M shares and warrants at $2.8825/unit.","Pre-funded warrants for 6.96M shares at $0.0001; common warrants expire May 28, 2029.","Financing co-led by Frazier Life Sciences and Janus Henderson; J.P. Morgan, Oppenheimer placement agents.","Proceeds to fund clinical programs including LX2006 efficacy readout expected by 2027.","Private placement expected to close May 28, 2025; resale registration to be filed by June 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162555,"accession_number":"0000950170-25-068534","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lexeo Therapeutics reports Q1 net loss $32.7M, cash $106.9M; LX2006 data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $32.7M ($0.99 per share) vs $21.7M ($0.77) in Q1 2024; R&D expense $17.2M, G&A $16.6M.","Cash, cash equivalents and investments of $106.9M expected to fund operations into 2027.","LX2006 in FA cardiomyopathy: interim data show 25% mean LVMI reduction and 115% avg frataxin increase; registrational study planned by early 2026.","LX2020 (PKP2-ACM): Cohort 1 showed 71% and 115% PKP2 increases; enrolling cohort 3; interim update expected H2 2025.","Redeployed $20M from non-cardiac pipeline; limited reduction in force of ~15% employees."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162554,"accession_number":"0000950170-25-051345","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lexeo reports positive interim Phase 1/2 data for LX2006 in FA cardiomyopathy; 25% LVMI reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Participants with abnormal LVMI at baseline achieved 25% mean reduction by 12 months or sooner.","High-dose cohort (Cohort 3) showed 115% mean increase in cardiac frataxin expression at 3 months.","LX2006 well tolerated; no Grade 3+ SAEs, no complement activation, no discontinuations.","FDA alignment on co-primary endpoints (LVMI >10% improvement, any frataxin increase) for registrational study.","Registrational study expected to initiate by early 2026; natural history study enrollment starts Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180555,"accession_number":"0000950170-25-043485","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lexeo Q4 net loss $25.9M; FDA aligns on LX2006 accelerated path; LX2020 shows protein expression increases","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.9M ($0.78/sh) for Q4 2024 vs $14.2M; FY net loss $98.3M ($3.09/sh) vs $66.4M.","Cash $128.5M expected to fund operations into 2027.","FDA agrees to use frataxin expression increase from baseline as co-primary endpoint for LX2006 pivotal study.","LX2020 cohort 1: PKP2 protein increased 71% and 115% from baseline; first participant saw 67% PVC reduction.","LX2020 cohort 2 fully enrolled; interim clinical data expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180554,"accession_number":"0000950170-25-004566","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lexeo Therapeutics posts updated corporate presentation; no material new information in 8-K","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation posted on website January 13, 2025, for investor and analyst meetings.","Presentation includes forward-looking statements on gene therapy trial plans and data timing.","No financial results, leadership changes, or other material events disclosed in this filing.","Risk factors from prior SEC filings are incorporated by reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197373,"accession_number":"0000950170-24-138224","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lexeo Therapeutics appoints Dr. Kyle Rasbach as CFO effective Dec 18, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kyle Rasbach appointed CFO; CEO R. Nolan Townsend steps down as principal financial officer.","Initial base salary $480,000, discretionary bonus target 40%; receives 40,875 RSUs and options for 245,250 shares.","Rasbach previously CFO at Zentalis, portfolio manager at Eventide, and analyst at T. Rowe Price and Cowen.","Severance includes 12 months salary, COBRA, and potential equity acceleration; if over $120M financing, unvested equity may continue vesting 24 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197372,"accession_number":"0000950170-24-125940","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Lexeo reaches FDA alignment on accelerated approval for LX2006; Q3 net loss $29.5M, cash $157M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA agreed on co-primary registrational endpoints (LVMI reduction and frataxin expression) for LX2006 accelerated approval.","Received RMAT designation for LX2006; completed enrollment in SUNRISE-FA Phase 1/2 (16 patients dosed to date).","LX2020 PKP2-ACM cohort 1 enrollment completed; initial safety/biodistribution data expected late Q1/Q2 2025.","Q3 net loss $29.5M ($0.89 per share) vs $20.1M year-ago; R&D $23.4M, G&A $8.1M.","Cash $157M expected into 2027; Tolga Tanguler (Alnylam exec) appointed to board."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197371,"accession_number":"0000950170-24-118569","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lexeo announces positive interim Phase 1/2 data for LX1001 gene therapy in APOE4 Alzheimer's","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LX1001 showed dose-dependent APOE2 expression in all participants with durability to 12 months.","CSF tau biomarkers (T-tau, P-tau181, P-tau217, P-tau231) reduced in >2/3 of participants relative to baseline.","No reports of ARIA; four SAEs reported, one hearing loss possibly related, repeat audiometry pending.","Company initiated FDA engagement; expects update on regulatory interactions and development plans in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197370,"accession_number":"0000950170-24-113764","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lexeo updates LX2020 cohort data timeline to late Q1/early Q2 2025; LX1001 data at CTAD Oct 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expects to share Cohort 1 data from LX2020 for PKP2-ACM in late Q1 or early Q2 2025.","Plans to present LX1001 data for APOE4-associated Alzheimer's at CTAD conference in Oct 2024.","Corporate presentation posted on website; used for investor meetings going forward.","No changes to financial guidance or capital structure disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213612,"accession_number":"0000950170-24-095054","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lexeo Q2 net loss $21.2M; positive interim gene therapy data in FA cardiomyopathy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.2M ($0.64 per share) vs $13.4M ($8.30) year ago; R&D $16.6M, G&A $7.0M.","Cash $175M expected to fund operations into 2027.","LX2006 for FA cardiomyopathy showed no treatment-related serious adverse events; FDA engagement for registrational study surrogate endpoints initiated.","Phase 1/2 trial for LX2020 (PKP2-ACM) recruiting; Cohort 1 data update on track for 2H 2024.","Tim Van Hauwermeiren (co-founder/CEO argenx) appointed to Board in July 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213611,"accession_number":"0000950170-24-083386","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lexeo positive Phase 1/2 data for LX2006 in FA cardio: LVMI -11.4% at 12mo, safe","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean LVMI reduction 11.4% at 12 months and 18.3% at 18 months in patients with elevated baseline LVMI.","75% of elevated-baseline patients achieved >10% LVMI reduction at 12 months.","hsTnI, a myocardial injury biomarker, reduced 53.3% on average at 12 months (n=5).","Frataxin expression increased post-treatment in all evaluable biopsies; no treatment-related SAEs.","Cohort 3 dosing started (1.2x10^12 vg/kg); DSMB endorsed progression; 13 total participants dosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213610,"accession_number":"0000950170-24-081942","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Lexeo Therapeutics appoints Tim Van Hauwermeiren, argenx CEO, to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective July 5, 2024; term expires at 2027 annual meeting.","Standard director comp: $40k annual cash, initial option for 36,000 shares, annual option for 18,000 shares.","Van Hauwermeiren is co-founder and CEO of argenx; built company to ~$25B market cap.","No arrangements or family relationships with Lexeo officers; standard indemnification agreement.","Appointed as independent, non-executive director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232818,"accession_number":"0000950170-24-078774","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lexeo Therapeutics stockholders elect Class I director, ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Mette Kirstine Agger elected Class I director with 14,499,254 FOR, 7,450,057 WITHHELD, 1,249,160 broker non-votes.","Ratification of KPMG LLP as auditor for FY2024 passed: 23,194,982 FOR, 3,088 AGAINST, 401 ABSTAIN.","Annual meeting held virtually on June 25, 2024; no other proposals were voted on."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232817,"accession_number":"0000950170-24-056260","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lexeo Q1 net loss $21.7M; cash $195.1M after $95M PIPE; pipeline milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 net loss $21.7M ($0.77/share) vs $18.7M ($11.58/share) in Q1 2023.","Cash and equivalents $195.1M at March 31, 2024, after $95M PIPE; runway into 2027.","LX2006 (FA cardiomyopathy) granted FDA Fast Track; interim readout mid-2024.","LX2020 (PKP2-ACM) Phase 1/2 trial recruiting; Cohort 1 data update expected 2H 2024.","LX1001 (APOE4 Alzheimer's) all-cohort interim data expected 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232816,"accession_number":"0000950170-24-046197","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Lexeo Therapeutics licenses full data and IP for LX2006 FA cardiomyopathy gene therapy from Cornell","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront fees total $600,000; potential regulatory milestones up to $2.1M and commercial milestones up to $100M.","Exclusive license to patent rights and non-exclusive know-how for AAVrh.10hFXN (LX2006), including right to reference IND.","11 participants dosed across two trials (Lexeo's SUNRISE-FA and Weill Cornell Phase 1A); no treatment-related SAEs reported.","Interim clinical data readout expected mid-2024, combining data from both studies with up to 18-month follow-up.","LX2006 has FDA Orphan Drug, Rare Pediatric Disease, and Fast Track designations for FA cardiomyopathy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232815,"accession_number":"0000950123-24-003417","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Bernard Davitian will not stand for reelection at Lexeo's 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bernard Davitian notified Lexeo on April 16, 2024, that he will not seek reelection.","His departure is effective at the June 25, 2024 annual meeting of stockholders.","The decision is not due to any disagreement with the company's operations or policies.","No replacement director has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232814,"accession_number":"0000950170-24-044598","cik":1907108,"company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lexeo Therapeutics receives FDA Fast Track designation for LX2006 gene therapy for FA cardiomyopathy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track designation for LX2006 (AAVrh.10hFXN gene therapy) for Friedreich's ataxia cardiomyopathy.","LX2006 aims to deliver functional frataxin gene to restore mitochondrial function in myocardial cells.","Phase 1/2 SUNRISE-FA trial ongoing to evaluate safety, tolerability, and preliminary efficacy in FA cardiomyopathy.","LX2006 previously received Rare Pediatric Disease and Orphan Drug designations; Fast Track may accelerate development.","FA cardiomyopathy is the leading cause of death among FA patients, with no approved treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":397319456.0510805,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}